NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England
Wednesday, 10 July 2024, 03:24
NICE Recommends Ebglyss for Moderate to Severe Atopic Dermatitis
The National Institute for Health and Care Excellence (NICE) has given its endorsement for the use of Ebglyss (lebrikizumab) in treating moderate to severe atopic dermatitis in eligible adolescents and adults under NHS England's guidance.
Key Points:
- Ebglyss is now recommended by NICE for atopic dermatitis.
- This decision provides new treatment opportunities for eligible patients.
- The therapy has demonstrated efficacy in managing symptoms of moderate to severe atopic dermatitis.
This approval by NICE represents a significant step forward in addressing the therapeutic needs of individuals with atopic dermatitis.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.